| abstract |
IT REFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING: A) AN APOPTOSIS PROMOTING COMPOUND THAT INHIBITS THE PROTEINS OF THE Bcl-2 FAMILY SUCH AS N- (4- (4 - ((2- (4-CHLOROPHENYL) -5,5 -DIMETHYL-1-CYCLOHEX-1-EN-1-IL) METHYL) PIPERAZIN-1-IL) BENZOIL) -4 - (((1R) -3- (MORFOLIN-4-IL) -1 - ((FENYLSULFANIL) METHYL) PROPYL) AMINO-3 - ((TRIFLUOROMETHYL) SULFONYL) BENZENOSULFONAMIDE (ABT-263) OR A SALT THEREOF; B) A CHALCOGEN ANTIOXIDANT SUCH AS N-ACETYL CYSTEINE, N-ACETHYLMETHIONINE, THIODIGLYTRYLLATE, DTHIBUTHYL OTHRICOLATE; C) A LIPID VEHICLE INCLUDING i) A PHOSPHOLIPID SUCH AS PHOSPHATIDYLCHOLINE, AND ii) A SOLUBILIZING AGENT SUCH AS MID-CHAIN TRIGLYCERIDES; D) A NON-PHOSPHOLIPID SURFACTANT SUCH AS POLYSORBATES; AND E) A CHELATING AGENT SUCH AS EDTA; WHERE SAID COMPOUND AND THE ANTIOXIDANT ARE FORMING A SOLUTION IN THE LIPID VEHICLE. SAID COMPOSITION IS FOR ORAL ADMINISTRATION, BEING USEFUL IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMA, CHRONIC AND ACUTE LYMPHOCYTIC LEUKEMIA |